FDA Issues Immediately in Effect Guidance on Ventilators During COVID-19

Today, the U.S. Food and Drug Administration (FDA) issued this immediately in effect guidance: Enforcement Policy for Ventilators and Accessories and Other Respiratory Devices During the Coronavirus Disease-2019 (COVID-19) Public Health Emergency.

The FDA believes the policy set forth in this guidance may help address urgent public health concerns by helping to expand the availability of devices that facilitate respiration, including ventilators and accessories.

SoftwareCPR Comments on FDA Emergency Guidance for Ventilators

This emergency use ventilator guidance temporarily exempts a wide range of changes to ventilator hardware and software from premarket review.  It also allows use of devices such as CPAP machines outside their labeled intended use and home use devices can be used in hospitals.  Even software changes to implement closed loop algorithms for oxygen titration can be released provided they currently have an IDE. Other software changes to adjust parameters or implant remote monitoring and control (to protect medical staff allowing them be in an isolated areas for monitor and adjustment) need no clearances (even if requiring changes or additions to the software architecture) including implementation of bluetooth or other wireless capability.

Cybersecurity controls are still expected.